{
  "id": "5c7161f47c78d69471000066",
  "type": "factoid",
  "question": "What is etarfolatide used for?",
  "ideal_answer": "Etarfolatide in the form of 99mTc-etarfolatide is used as a companion imaging agent",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26238440",
    "http://www.ncbi.nlm.nih.gov/pubmed/24667717",
    "http://www.ncbi.nlm.nih.gov/pubmed/25457975",
    "http://www.ncbi.nlm.nih.gov/pubmed/27084348",
    "http://www.ncbi.nlm.nih.gov/pubmed/24742319",
    "http://www.ncbi.nlm.nih.gov/pubmed/24127448"
  ],
  "snippets": [
    {
      "text": "99mTc-etarfolatide, an imaging agent for folate receptor in healthy Japanese adults",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26238440",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " In contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)Tc-etarfolatide ((99m)Tc-EC20), is in development for use as a companion diagnostic with the FR\u03b1-targeted folate conjugate,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25457975",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE\nTechnetium etarfolatide ((99m)Tc-EF) is a radioactive diagnostic imaging agent that was developed to assess the expression of folate receptors in tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26238440",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE\nThrough binding to folate receptor-\u03b2 (FR-\u03b2), the new (99m)Tc-EC20 (Etarfolatide) imaging technique detects activated but not resting macrophages in\u00a0vivo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27084348",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)Tc-etarfolatide ((99m)Tc-EC20), is in development for use as a companion diagnostic with the FR\u03b1-targeted folate conjugate, vintafolide (EC145), to identify patients whose tumors express FR\u03b1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25457975",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE Technetium etarfolatide ((99m)Tc-EF) is a radioactive diagnostic imaging agent that was developed to assess the expression of folate receptors in tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26238440",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide).<AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">This report examines (99m)Tc-etarfolatide imaging to identify the presence of folate receptor (FR) on tumors of women with recurrent/refractory ovarian or endometrial cancer and correlates expression with response to FR-targeted therapy (vintafolide). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24667717",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)Tc-etarfolatide ((99m)Tc-EC20), is in development for use as a companion diagnostic with the FR\u03b1-targeted folate conjugate, vintafolide (EC145), to identify patients whose tumors express FR\u03b1. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25457975",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We review the development of vintafolide (EC145), a folic acid-desacetylvinblastine conjugate, the predictive utility of a FR-targeted imaging agent, technetium-(99)m-etarfolatide (EC20), the challenges in proving survival advantage, and other approaches to exploiting FR as a target in ovarian cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24742319",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The utility of an FR-targeted imaging agent, (99m)Tc-etarfolatide (EC20), in selecting patients likely to benefit from vintafolide was also examined. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24127448",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "<b>BACKGROUND</b>: This report examines (99m)Tc-etarfolatide imaging to identify the presence of folate receptor (FR) on tumors of women with recurrent/refractory ovarian or endometrial cancer and correlates expression with response to FR-targeted therapy (vintafolide).<br><b>PATIENTS AND METHODS</b>: In this phase II, single-arm, multicenter study, patients with advanced ovarian cancer were imaged with (99m)Tc-etarfolatide before vintafolide treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24667717",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "companion imaging agent"
}